Unknown

Dataset Information

0

Use of capture-based next-generation sequencing to detect ALK fusion in plasma cell-free DNA of patients with non-small-cell lung cancer.


ABSTRACT: Capture-based next-generation sequencing (NGS) is a potentially useful diagnostic method to measure tumor tissue DNA in blood as it can identify concordant mutations between cell-free DNA (cfDNA) and primary tumor DNA in lung cancer patients. In this study, the sensitivity, specificity and accuracy of capture-based NGS for detecting ALK fusion in plasma cfDNA was assessed. 24 patients with tissue ALK-positivity and 15 who did not harbor ALK fusion were enrolled. 13 ALK-positive samples were identified by capture-based NGS among the 24 samples with tissue ALK-positivity. In addition to EML4-ALK, 2 rare fusion types (FAM179A-ALK and COL25A1-ALK) were also identified. The overall sensitivity, specificity and accuracy for all cases were 54.2%, 100% and 71.8%, respectively. For patients without distant metastasis (M0-M1a) and patients with distant metastasis (M1b), the sensitivities were 28.6% and 64.7%, respectively. In the 15 patients who received crizotinib, the estimated median PFS was 9.93 months. Thus, captured-based NGS has acceptable sensitivity and excellent specificity for the detection of ALK fusion in plasma cfDNA, especially for patients with distant metastasis. This non-invasive method is clinically feasible for detecting ALK fusion in patients with advanced-stage NSCLC who cannot undergo traumatic examinations or have insufficient tissue samples for molecular tests.

SUBMITTER: Cui S 

PROVIDER: S-EPMC5356840 | biostudies-other | 2017 Jan

REPOSITORIES: biostudies-other

altmetric image

Publications

Use of capture-based next-generation sequencing to detect ALK fusion in plasma cell-free DNA of patients with non-small-cell lung cancer.

Cui Shaohua S   Zhang Wei W   Xiong Liwen L   Pan Feng F   Niu Yanjie Y   Chu Tianqing T   Wang Huimin H   Zhao Yizhuo Y   Jiang Liyan L  

Oncotarget 20170101 2


Capture-based next-generation sequencing (NGS) is a potentially useful diagnostic method to measure tumor tissue DNA in blood as it can identify concordant mutations between cell-free DNA (cfDNA) and primary tumor DNA in lung cancer patients. In this study, the sensitivity, specificity and accuracy of capture-based NGS for detecting ALK fusion in plasma cfDNA was assessed. 24 patients with tissue ALK-positivity and 15 who did not harbor ALK fusion were enrolled. 13 ALK-positive samples were iden  ...[more]

Similar Datasets

| S-EPMC4078241 | biostudies-literature
| S-EPMC7225153 | biostudies-literature
| S-EPMC7003348 | biostudies-literature
| S-EPMC7591296 | biostudies-literature
| S-EPMC5323149 | biostudies-literature
| S-EPMC6858956 | biostudies-literature
| S-EPMC8488792 | biostudies-literature
| S-EPMC4592417 | biostudies-literature
| S-EPMC5624911 | biostudies-literature
| S-EPMC9070798 | biostudies-literature